Edgewise Therapeutics (EWTX) said Wednesday it promoted Chief Business Officer Behrad Derakhshan to chief operating officer.
The company also said it named Robert Blaustein as chief development officer.
Blaustein previously served as associate vice president and the atherosclerosis section head in the atherosclerosis and metabolism clinical research department at Merck (MRK), Edgewise said.
Edgewise said the changes to its executive team took effect immediately.
The company's shares were down 4% in recent trading.
Price: 26.31, Change: -1.08, Percent Change: -3.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.